Literature DB >> 11028665

Borg scores before and after challenge with adenosine 5'-monophosphate and methacholine in subjects with COPD and asthma.

S R Rutgers1, N H ten Hacken, G H Koeter, D S Postma.   

Abstract

Dyspnoea differs between subjects with chronic obstructive pulmonary disease (COPD) and asthma, partly because the underlying mechanisms for bronchoconstriction differ. This study investigated the possible role of inflammation and the contribution of clinical variables on dyspnoea in subjects with COPD and asthma. Forty-eight smoking subjects with COPD and 21 nonsmoking subjects with asthma, were challenged with adenosine 5'-monophosphate (AMP) and methacholine. The Borg score was assessed before and after each challenge. Mean increases in Borg score (per percentage decrease in baseline forced expiratory volume in one second (FEV1)) were significantly smaller in COPD than in asthma (p<0.01), values being 0.055 and 0.045 in COPD and 0.122 and 0.093 in asthma respectively. This difference was largely due to the fact that one-third of the subjects with COPD did not increase their Borg score during bronchoconstriction. The increase in Borg tended to be larger during AMP than during methacholine challenge, both in asthma and COPD. Changes in Borg scores were explained by age in COPD and by the Borg score before AMP challenge in asthma. The authors conclude that perception of dyspnoea during adenosine 5'-monophosphate and methacholine induced bronchoconstriction is lower in chronic obstructive pulmonary disease than in asthma and that age contributes to this difference. As adenosine 5'-monophosphate is regarded as an indirect marker of airway inflammation, the results suggest that inflammation is not important because both groups showed similar responses on such provocations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11028665     DOI: 10.1034/j.1399-3003.2000.016003486.x

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  5 in total

Review 1.  Beta2-agonists and bronchial hyperresponsiveness.

Authors:  Clive P Page; Domenico Spina
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

Review 2.  Chronic obstructive pulmonary disease: an update on diagnosis and management issues in older adults.

Authors:  Shoab A Nazir; Marcia L Erbland
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

3.  Dyspnea assessment and adverse events during sputum induction in COPD.

Authors:  Demosthenes Makris; Nikolaos Tzanakis; Joanna Moschandreas; Nikolaos M Siafakas
Journal:  BMC Pulm Med       Date:  2006-06-29       Impact factor: 3.317

Review 4.  Therapeutic applications.

Authors:  Stephen Tilley; Jon Volmer; Maryse Picher
Journal:  Subcell Biochem       Date:  2011

5.  Relationship between Dyspnea Descriptors and Underlying Causes of the Symptom; a Cross-sectional Study.

Authors:  Seyyed Mohammad Ali Sajadi; Alireza Majidi; Fahimeh Abdollahimajd; Fatemeh Jalali
Journal:  Emerg (Tehran)       Date:  2017-03-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.